[Skip to Navigation]
February 2, 2022

Hair Are the Rankings—5-α Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia

Author Affiliations
  • 1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Department of Dermatology, Massachusetts General Hospital, Boston
JAMA Dermatol. 2022;158(3):242-243. doi:10.1001/jamadermatol.2021.5625

Androgenetic alopecia (AGA) in men is the most common type of hair loss in the US, affecting 50% of men by age 50 and up to 90% of men in their lifetime.1 AGA moderately impairs health-related quality of life and is associated with low self-esteem and depression.1 Despite the outcomes associated with this condition and its high prevalence, treatment options remain limited, with topical minoxidil, oral finasteride 1 mg, and low-level light therapy being the only US Food and Drug Administration–approved therapies. In an attempt to increase therapeutic options for patients, off-label use of oral minoxidil, oral dutasteride, and higher doses of oral finasteride and topical minoxidil are increasingly reported in the literature.

Add or change institution